All Stories

  1. Choosing pharmacotherapy for ILD in patients with connective tissue disease

    Article • Breathe, December 2021, European Respiratory Society (ERS)

    Phil Molyneaux

  2. The burden of progressive fibrotic interstitial lung disease across the UK

    Article • European Respiratory Journal, March 2021, European Respiratory Society (ERS)

    Phil Molyneaux

  3. Eligibility for anti-fibrotic therapy of patients in British Thoracic Society (BTS) UK IPF Registry varies according to the reference values used to calculate FVC

    Article • September 2020, European Respiratory Society (ERS)

    Phil Molyneaux

  4. Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent

    Article • European Respiratory Journal, January 2020, European Respiratory Society (ERS)

    Phil Molyneaux

  5. The Challenging Road of Moving from Association to Causation for Microbiome Research in Idiopathic Pulmonary Fibrosis

    Article • American Journal of Respiratory and Critical Care Medicine, May 2019, American Thoracic Society

    Phil Molyneaux

  6. The potential impact of azithromycin in idiopathic pulmonary fibrosis

    Article • European Respiratory Journal, February 2019, European Respiratory Society (ERS)

    Phil Molyneaux

  7. Host–Microbial Interactions in Idiopathic Pulmonary Fibrosis

    Article • American Review of Respiratory Disease, June 2017, American Thoracic Society

    Phil Molyneaux

  8. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib

    Article • Drug Design Development and Therapy, June 2013, Taylor & Francis

    Toby Maher, Phil Molyneaux

  9. Lung microbiology and exacerbations in COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, August 2012, Taylor & Francis

    Phil Molyneaux